Dr. Ryo-ichi Yoshimura of the Department of Radiation Therapeutics and Oncology at the Institute of Science Tokyo (Science Tokyo) has published "Efficacy and safety of diffusing alpha-emitter radiation therapy (DaRT) for head and neck cancer recurrence after radiotherapy" online in the International Journal of Clinical Oncology.
===
This study, conducted by a collaborative team of clinicians and researchers from leading Japanese institutions: the Institute of Science Tokyo, the National Cancer Center Hospital, and Tohoku University Hospital, evaluates the efficacy and safety of Diffusing Alpha-emitter Radiation Therapy (DaRT) for recurrent head and neck cancer (rHNC) after radiotherapy. Their findings offer valuable insights into the potential of DaRT as a novel treatment modality for this challenging condition.
HekaBio is partnering with Alpha Tau Medical to bring the groundbreaking Alpha DaRT (Diffusing Alpha Radiation Therapy) to Japan, offering a new treatment option for recurrent head and neck cancer.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Comentários